Meeting slides
Suggested Readings

Additional Abstracts From the 2017 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting.

November 2017; San Diego, California.

Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Anderson J, et al. Arthritis Care Res (Hoboken). 2012;64(5):640-647.

Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration.

Bianchi G, et al. Adv Ther. 2016;33(3):369-378

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Cohen SB, et al. Ann Rheum Dis. 2017;76(7):1253-1262.

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.

Dougados M, et al. Ann Rheum Dis. 2017;76(1):88-95.

Long term safety of filgotinib in the treatment of rheumatoid arthritis: week 84 data from a phase 2b open-label extension study.

Genovese MC, et al. Arthritis Rheumatol. 2017;69 (suppl 10). Abstract 1909.

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.

Fleischmann R, et al. Lancet. 2017;390(10093):457-468.

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.

Fleischmann R, et al. Clin Rheumatol. 2017;36(1):15-24.

Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies.

Fleischmann R, et al. RMD Open. 2017;3(2):e000491.

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.

Genovese MC, et al. Rheumatology. 2018;57(5):900-908.

Upadacitinib (ABT-494) in patients with active rheumatoid arthritis and inadequate response or intolerance to biological DMARDs: a phase 3 randomized, placebo-controlled, double-blind study of a selective JAK-1 inhibitor.

Genovese MC, et al. Arthritis Rheumatol. 2017;69(suppl 10). Abstract 10L.

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).

Kavanaugh A, et al. Ann Rheum Dis. 2017;76(6):1009-1019.

No effect of baseline serum CRP levels on clinical efficacy parameters in rheumatoid arthritis patients treated with filgotinib: post hoc analysis from two phase 2B studies.

Kavanaugh A, et al. Arthritis Rheumatol. 2017;69 (suppl 10) Abstract 537.

Time to achieve moderate/low disease activity and remission in RA patients on baricitinib compared to adalimumab, methotrexate, and placebo.

Keystone EC, et al. Arthritis Rheumatol. 2017;69 (suppl 10). Abstract 513.

Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate.

Kivitz AJ, et al. Arthritis Rheumatol. 2017;69(4):709-719.

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.

Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.

Cycling versus swapping in patients with rheumatoid arthritis with an inadequate response to at least one tumor necrosis factor alpha inhibitor: a systematic review and meta-analysis of observational study.

Lopez-Olivo MA, et al. Arthritis Rheumatol. 2017;69(suppl 10):Abstract 2483.

Pathogenetic insights from the treatment of rheumatoid arthritis.

McInnes IB, Schett G. Lancet. 2017;389(10086):2328-2337.

Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk?

Scott IC, et al. Drug Saf. 2018 Mar 2. [Epub ahead of print].

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).

Westhovens R, et al. Ann Rheum Dis. 2017;76(6):998-1008.

Linked Resources

Clinical Practice Guidelines

2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.

Singh JA, et al. Arthritis Rheumatol. 2016;68(1):1-26.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Smolen JS, et al. Ann Rheum Dis. 2013;72(4):482-492.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, et al. Ann Rheum Dis. 2017;76(6):960-977.

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Smolen JS, et al. Ann Rheum Dis. 2016;75(1):3-15.

Patient Resources

American College of Rheumatology Disease Overview

The American College of Rheumatology has published a concise overview to help patients and caregivers learn more about rheumatoid arthritis and to provide tips for living well with this rheumatic disease.

American College of Rheumatology Patient Education Videos

The American College of Rheumatology has produced a library of videos about the impact of rheumatic disease, what to do when diagnosed with rheumatic disease, when to see a rheumatologist, and what patients have to say about their experiences of living with rheumatic disease.

Arthritis Foundation

The Arthritis Foundation provides self-care tools and resources covering treatment options, pain management, diet and exercise, and common comorbidities associated with many different arthritic conditions.

EULAR ‘Don’t Delay, Connect Today’ Campaign

This European League Against Rheumatism (EULAR) Campaign aims to raise awareness of the importance of early diagnosis in preventing further damage to those living with rheumatic and musculoskeletal diseases, and to encourage timely access to evidence-based treatment.

European League Against Rheumatism

EULAR is an organization that represents people with arthritis/rheumatism, health professionals, and scientific societies of rheumatology of all the European nations.

Health Topics: Rheumatoid Arthritis

A resource from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about this disease.

Rheumatoid Arthritis Support Network

The Rheumatoid Arthritis Support Network provides up-to-date information for patients with rheumatoid arthritis, including links to patient support groups, blogs written by patients with rheumatoid arthritis, resources to help pay for medications, and smart device apps to help track symptoms over time.

Related activities

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Faculty: Allan Gibofsky, MD, JD, MACR, FACP, FCLM; Ralf Thiele, MD, FACR, RhMSUS
Release: 07/11/2018
Expiration: 07/11/2019
1.00 CME/CE

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

Faculty: Rieke Alten, MD; Joel Kremer, MD, FACP; Josef Smolen, MD
Release: 10/10/2018
Expiration: 10/10/2019